---
title: "NIH halts low-dose rivaroxaban arm in stroke trial due to safety review findings in Phase 3 CAPTIVA trial."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275803419.md"
description: "The NIH has halted the low-dose rivaroxaban arm of the Phase 3 CAPTIVA stroke prevention trial due to safety concerns. An independent review found increased safety events and no potential benefits compared to clopidogrel. The decision followed recommendations from the Data Safety and Monitoring Board, citing a predetermined futility threshold. Rivaroxaban is developed by Bayer AG and Johnson & Johnson."
datetime: "2026-02-12T20:00:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275803419.md)
  - [en](https://longbridge.com/en/news/275803419.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275803419.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275803419.md) | [繁體中文](https://longbridge.com/zh-HK/news/275803419.md)


# NIH halts low-dose rivaroxaban arm in stroke trial due to safety review findings in Phase 3 CAPTIVA trial.

The National Institutes of Health (NIH) has discontinued the low-dose rivaroxaban arm of its Phase 3 CAPTIVA stroke prevention trial. The trial aimed to compare the efficacy of experimental arms (rivaroxaban or ticagrelor, or both) against clopidogrel in reducing the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death. The decision came after an independent safety review revealed increased safety events and a lack of potential benefits. The NIH's National Institute of Neurological Disorders and Stroke, which sponsors the trial, acted on the recommendation of the Data Safety and Monitoring Board to halt the rivaroxaban group due to safety concerns and a predetermined futility threshold. Rivaroxaban is a product of Bayer AG and Johnson & Johnson. Full story on Benzinga.com.

### Related Stocks

- [Bayer Aktiengesellschaft (BAYRY.US)](https://longbridge.com/en/quote/BAYRY.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Bayer AG (BAYN.DE)](https://longbridge.com/en/quote/BAYN.DE.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Johnson & Johnson (JNJ.US)](https://longbridge.com/en/quote/JNJ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Bayer Aktiengesellschaft (BAYZF.US)](https://longbridge.com/en/quote/BAYZF.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Bayer Crop Science Launches 2026 Opportunity Scholarship Program | BAYRY Stock News](https://longbridge.com/en/news/279287837.md)
- [Johnson & Johnson Seeks Tecvayli Indication Extension in EU](https://longbridge.com/en/news/278543736.md)
- [Bayer takes its battle on pesticide liability to Kansas](https://longbridge.com/en/news/278745220.md)
- [Johnson & Johnson Reports Promising Early Data for Erdafitinib Bladder Insert in Early Study](https://longbridge.com/en/news/279076688.md)
- [Trevi Therapeutics Maps Phase III Path and Runway](https://longbridge.com/en/news/279703997.md)